Advertisement
YOU ARE HERE: LAT HomeCollectionsVivus Inc
IN THE NEWS

Vivus Inc

FEATURED ARTICLES
BUSINESS
May 21, 1997 | (Bloomberg News)
Vivus Inc. said the group that licensed the patent to it for its impotence drug has dropped a lawsuit alleging Vivus defrauded the group during licensing negotiations. The licensers alleged in their suit, filed in Texas, that they were defrauded during the negotiations that led to a new license agreement between the group and Vivus in December 1992, the company said.
ARTICLES BY DATE
BUSINESS
March 9, 1999 | From Reuters
Shares of Vivus Inc., a maker of products for relieving sexual dysfunction, more than doubled Monday amid expectations that the company could revive its flagging fortunes with a new product targeted at women. Mountain View, Calif.-based Vivus, whose stock sank after the 1998 launch of Pfizer's impotence drug, Viagra, rose $2.63, or 120%, to close at $4.81 on Nasdaq after the company announced it had been granted a patent covering the treatment of female sexual dysfunction.
Advertisement
BUSINESS
August 26, 1998 | Bloomberg News
Vivus Inc. said Tuesday it hired investment banker Credit Suisse First Boston to help it explore options, including selling itself, as the impotence-treatment maker has lost sales to Pfizer Inc.'s Viagra. The Mountain View-based company said one of the options under consideration is finding a large company to help market its Muse impotence treatment to the thousands of primary-care physicians who are prescribing Viagra. Vivus' stock has fallen more than 80% in the last year.
BUSINESS
August 26, 1998 | Bloomberg News
Vivus Inc. said Tuesday it hired investment banker Credit Suisse First Boston to help it explore options, including selling itself, as the impotence-treatment maker has lost sales to Pfizer Inc.'s Viagra. The Mountain View-based company said one of the options under consideration is finding a large company to help market its Muse impotence treatment to the thousands of primary-care physicians who are prescribing Viagra. Vivus' stock has fallen more than 80% in the last year.
BUSINESS
March 9, 1999 | From Reuters
Shares of Vivus Inc., a maker of products for relieving sexual dysfunction, more than doubled Monday amid expectations that the company could revive its flagging fortunes with a new product targeted at women. Mountain View, Calif.-based Vivus, whose stock sank after the 1998 launch of Pfizer's impotence drug, Viagra, rose $2.63, or 120%, to close at $4.81 on Nasdaq after the company announced it had been granted a patent covering the treatment of female sexual dysfunction.
BUSINESS
December 11, 1997 | Reuters
Vivus Inc. said its fourth-quarter profit will fall short of estimates as production delays cut sales of its impotence drug. A delay in opening a second factory and lower production at the existing one could cut sales of the drug by 25% in the fourth quarter from the third quarter. The delays will also cut shipments to the U.S. and Europe in the first two quarters of 1998, the company said.
BUSINESS
July 10, 1998 | From Times Wire Reports
The spectacular debut of the impotence drug Viagra helped pharmaceutical giant Pfizer Inc. post a 38% increase in second-quarter profit, the company said Thursday. Meanwhile, California drug maker Vivus Inc. reported a second-quarter loss because demand for its Muse treatment for impotence plunged after Viagra hit the market.
BUSINESS
June 4, 1998 | Bloomberg News
Vivus Inc. shares fell 19% after new research showed that the company's impotence treatment, a pellet inserted in the urethra, is less effective than reported in earlier tests. A study of 115 men suffering from impotence found that only 27% treated with the Muse product were able to obtain an erection they deemed sufficient for intercourse. That's compared with a response rate of 60% to 70% reported in a company-sponsored study described in a 1997 New England Journal of Medicine article.
BUSINESS
April 10, 1998
* Half Moon Bay-based Odwalla Inc. reported a fiscal second-quarter net loss of $274,000, or 5 cents per share, compared with a net loss of $3 million, or 61 cents, a year ago, which included a pretax charge of $102,000 for recall and related costs. * Mountain View-based Vivus Inc. reported a wider-than-expected first-quarter loss of $2.39 million, or 7 cents per diluted share, contrasted with a profit of $9.5 million, or 27 cents, a year ago.
BUSINESS
September 7, 1993 | James M. Gomez / Times staff writer
Oxford Bioscience Partners of Costa Mesa, which also has an office in Stamford, Conn., has also just received some fresh money. The venture capital concern, which specializes in the health care industry--including biotechnology, biomedical and health services--has just raised nearly $54 million to invest in cash-needy businesses in Orange County and throughout the nation. "We are looking at a number of companies right now," said fund partner Edmund M. Olivier.
BUSINESS
July 10, 1998 | From Times Wire Reports
The spectacular debut of the impotence drug Viagra helped pharmaceutical giant Pfizer Inc. post a 38% increase in second-quarter profit, the company said Thursday. Meanwhile, California drug maker Vivus Inc. reported a second-quarter loss because demand for its Muse treatment for impotence plunged after Viagra hit the market.
BUSINESS
December 11, 1997 | Reuters
Vivus Inc. said its fourth-quarter profit will fall short of estimates as production delays cut sales of its impotence drug. A delay in opening a second factory and lower production at the existing one could cut sales of the drug by 25% in the fourth quarter from the third quarter. The delays will also cut shipments to the U.S. and Europe in the first two quarters of 1998, the company said.
BUSINESS
May 21, 1997 | (Bloomberg News)
Vivus Inc. said the group that licensed the patent to it for its impotence drug has dropped a lawsuit alleging Vivus defrauded the group during licensing negotiations. The licensers alleged in their suit, filed in Texas, that they were defrauded during the negotiations that led to a new license agreement between the group and Vivus in December 1992, the company said.
NEWS
April 27, 2012 | By Eryn Brown, Los Angeles Times / for the Booster Shots blog
The U.S. Food and Drug Administrationapproved Stendra, a new drug to treat erectile dysfunction in men, on Friday. Like Viagra, Cialis and Levitra, Stendra (generic name avanafil) is a pill, and is in a class of drugs called PDE5 inhibitors. These work by increasing blood flow to the penis. Patients can take Stendra as needed 30 minutes before sexual activity, the FDA said in a statement released Friday. One possible advantage of the new drug?  Vivus Inc., the company that markets Stendra, has claimed that it will provide erections in 15 minutes or less - in about half as much time as Viagra can.  Like other PDE5 inhibitors, Stendra is not recommended for men who take nitrates for chest pain, because taking both drugs can cause a rapid drop in blood pressure, the FDA said. Side effects reported during clinical trials of Stendra included headache and cold-like symptoms.  The National Kidney and Urologic Diseases Information Clearinghouse provides information about erectile dysfunction and its treatment at this website .
Los Angeles Times Articles
|